These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 6496458)

  • 1. Treatment of polycythemia vera with hydroxyurea.
    Donovan PB; Kaplan ME; Goldberg JD; Tatarsky I; Najean Y; Silberstein EB; Knospe WH; Laszlo J; Mack K; Berk PD
    Am J Hematol; 1984; 17(4):329-34. PubMed ID: 6496458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.
    Weinfeld A; Swolin B; Westin J
    Eur J Haematol; 1994 Mar; 52(3):134-9. PubMed ID: 8168592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.
    West WO
    South Med J; 1987 Mar; 80(3):323-7. PubMed ID: 3824016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
    Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemic transformation in polycythemia vera: analysis of risk factors.
    Nand S; Messmore H; Fisher SG; Bird ML; Schulz W; Fisher RI
    Am J Hematol; 1990 May; 34(1):32-6. PubMed ID: 2327402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
    Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
    Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of polycythemia vera with hydroxyurea.
    Sharon R; Tatarsky I; Ben-Arieh Y
    Cancer; 1986 Feb; 57(4):718-20. PubMed ID: 3943010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
    Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E; Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
    Cancer; 2014 Feb; 120(4):513-20. PubMed ID: 24258498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.
    Mavrogianni D; Viniou N; Michali E; Terpos E; Meletis J; Vaiopoulos G; Madzourani M; Pangalis G; Yataganas X; Loukopoulos D
    Int J Hematol; 2002 May; 75(4):394-400. PubMed ID: 12041671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.
    Barbui T; Vannucchi AM; Finazzi G; Finazzi MC; Masciulli A; Carobbio A; Ghirardi A; Tognoni G
    Am J Hematol; 2017 Nov; 92(11):1131-1136. PubMed ID: 28699191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17.
    Tóthová E; Fricová M; Stecová N; Hlebasková M; Kafková A; Raffac S; Guman T; Svorcová E; Nebesnáková E
    Neoplasma; 2001; 48(5):389-92. PubMed ID: 11845984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
    Michiels JJ; Barbui T; Finazzi G; Fuchtman SM; Kutti J; Rain JD; Silver RT; Tefferi A; Thiele J
    Leuk Lymphoma; 2000 Jan; 36(3-4):239-53. PubMed ID: 10674896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can pegylated interferon improve the outcome of polycythemia vera patients?
    Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D
    J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
    Alvarez-Larrán A; Pérez-Encinas M; Ferrer-Marín F; Hernández-Boluda JC; Ramírez MJ; Martínez-López J; Magro E; Cruz Y; Mata MI; Aragües P; Fox ML; Cuevas B; Montesdeoca S; Hernández-Rivas JA; García-Gutiérrez V; Gómez-Casares MT; Steegmann JL; Durán MA; Gómez M; Kerguelen A; Bárez A; García MC; Boqué C; Raya JM; Martínez C; Albors M; García F; Burgaleta C; Besses C;
    Haematologica; 2017 Jan; 102(1):103-109. PubMed ID: 27686377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea.
    Cacciola E; Cacciola RR; Guglielmo P; Stagno F; Giustolisi R
    Haematologica; 1999 Aug; 84(8):755-6. PubMed ID: 10457418
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group.
    Najean Y; Rain JD
    Blood; 1997 Apr; 89(7):2319-27. PubMed ID: 9116275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment with hydroxyurea of polycythemia vera in a 11 year-old child].
    Vodoff MV; Nelken B; Vic P; Farriaux JP
    Arch Pediatr; 1996 Sep; 3(9):870-3. PubMed ID: 8949347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
    Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
    J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.